Effects of physostigmine and lecithin on memory in Alzheimer disease.
Because there is evidence that central cholinergic mechanisms are depleted in dementia, we studied the effects of central cholinergic augmentation on the memory of 5 patients with Alzheimer disease. Patients received placebo, lecithin, physostigmine, or lecithin plus physostigmine in a double-blind study using titrated doses of the acetylcholinesterase inhibitor physostigmine. Memory was evaluated with alternate forms of the selective reminding procedure. Compared with lecithin alone, the combination of physostigmine and lecithin consistently enhanced memory storage and retrieval; physostigmine without lecithin produced no memory facilitation. The strategy of combining a cholinergic agonist and precursor holds promise, although a larger clinical trial is needed.
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D003704:Dementia / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D010713:Phosphatidylcholines / Q000494:pharmacology* / Q000627:therapeutic use; D010830:Physostigmine / Q000494:pharmacology* / Q000627:therapeutic use
D010713:Phosphatidylcholines; D010830:Physostigmine